Women aged 40 years and older have a 50% greater risk for chronic obstructive pulmonary disease (COPD) vs men in the same age group, according to study findings published in BMJ Open Respiratory ...

Long-term exposure to particulate matter in patients with pulmonary arterial hypertension increases risk for lung transplantation or death.

Merrill H. Stewart, MD, Ochsner Health, explains how his practice takes advantage of downtime during cardiologist ...

Background Chronic obstructive pulmonary disease (COPD) is a common preventable and treatable chronic respiratory disease, which affects 210 million people globally. Global and national guidelines ...

Introduction In patients with chronic obstructive pulmonary disease (COPD), the risk of certain cardiovascular (CV) events is increased by threefold to fivefold in the year following acute ...

Tezepelumab has received an FDA breakthrough therapy designation as a maintenance treatment for patients with moderate to very severe COPD characterized by an eosinophilic phenotype, according to ...

Background: Chronic obstructive pulmonary disease (COPD) is the fourth most common cause of death worldwide. It is caused primarily by cigarette smoking. Given its importance, it is remarkable that ...

Background Conventional measures to evaluate COPD may fail to capture systemic problems, particularly musculoskeletal weakness and cardiovascular disease. Identifying these manifestations and ...

Pulmonary hypertension occurs when there is an abnormally high pressure in the blood vessels between the lungs and the heart. Skip to main content. ... lung health education, and more. Make a Donation ...

Among patients with COPD and type 2 inflammation, investigator-reported emphysema did not change benefits seen with dupilumab ...

COPD patients who receive intensive guidance from a hospital pharmacist during their stay use their inhalation medication ...

PharmTech Group spoke with Andy Burns, vice-president of MDI Business Development at Kindeva, about trends he is observing in the pulmonary drug delivery field as part of our preview of the BIO ...